Maxim Group raised its price target for Abeona Therapeutics (NASDAQ:ABEO) to $35 from $17, citing advances in the gene therapy space and comparatives to competitor, AveXis.Read More
Roth Capital Markets launched coverage on Mateon Therapeutics (OTCQX:MATN) with a “buy” rating and $2 price target. The stock closed at 77 cents on April 19.Read More
Ladenburg Thalmann initiated coverage of Bellicum Pharmaceuticals (NASDAQ:BLCM) with a “buy” rating and $31 price target. The stock closed at $19.16 on Nov. 29.Read More
Mackie Research Capital raised its price target for Profound Medical (TSX-V:PRN) to $4.40 from $3.30 after the company reported third quarter results. The stock closed at $1 on Thursday.
Analyst Andre Uddin writes that his new valuation is based on applying a multiple of 4.2 times enterprise value to sales on a 2019 sales estimate to $86-million, discounted back by 50%.Read More
Titan Pharmaceutical’s (NASDAQ:TTNP) Probuphine six-month implant of sublingual buprenorphine continues to attract widespread media attention for its ability to treat addiction to opioids.
Independent TV station, WHDT, in Stuart, FL. has produced a segment on Probuphine with Dr. Stuart Segal and one of his patients, who was successfully weaned off her use of opioids.Read More
Profound Medical (TSX-V:PRN) has received investigational device exemption (IDE) approval from the FDA for a multicenter pivotal clinical trial to evaluate the efficacy of the TULSA-PRO System in patients with localized prostate cancer.
TULSA-PRO, which has received CE Mark in Europe, combines real-time MRI with transurethral robotically-driven ultrasound and closed-loop thermal feedback control, providing a highly precise prostate treatment tailored to patient-specific anatomy.Read More